作者
Julian Stumpf, Torsten Siepmann, Tom Lindner, Claudia Karger, Jörg Schwöbel, Leona Anders, Robert Faulhaber-Walter, Jens Schewe, Heike Martin, Holger Schirutschke, Kerstin Barnett, Jan Hüther, Petra Müller, Torsten Langer, Thilo Pluntke, Kirsten Anding-Rost, Frank Meistring, Thomas Stehr, Annegret Pietzonka, Katja Escher, Simon Cerny, Hansjörg Rothe, Frank Pistrosch, Harald Seidel, Alexander Paliege, Joachim Beige, Ingolf Bast, Anne Steglich, Florian Gembardt, Friederike Kessel, Hannah Kröger, Patrick Arndt, Jan Sradnick, Kerstin Frank, Anna Klimova, René Mauer, Xina Grählert, Moritz Anft, Arturo Blazquez-Navarro, Timm H Westhoff, Ulrik Stervbo, Torsten Tonn, Nina Babel, Christian Hugo
发表日期
2021/10/1
期刊
The Lancet Regional Health–Europe
卷号
9
出版商
Elsevier
简介
Background
Dialysis and kidney transplant patients are vulnerable populations for COVID-19 related disease and mortality.
Methods
We conducted a prospective study exploring the eight week time course of specific cellular (interferon-γ release assay and flow cytometry) or/and humoral immune responses (ELISA) to SARS-CoV-2 boost vaccination in more than 3100 participants including medical personnel, dialysis patients and kidney transplant recipients using mRNA vaccines BNT162b2 or mRNA-1273.
Results
SARS-CoV-2-vaccination induced seroconversion efficacy in dialysis patients was similar to medical personnel (> 95%), but markedly impaired in kidney transplant recipients (42%). T-cellular immunity largely mimicked humoral results. Major risk factors of seroconversion failure were immunosuppressive drug number and type (belatacept, MMF-MPA, calcineurin-inhibitors) as well as vaccine type …
学术搜索中的文章
J Stumpf, T Siepmann, T Lindner, C Karger… - The Lancet Regional Health–Europe, 2021